American Academy of Family Physicians
About UsNews & PublicationsMembersCME CenterClinical & ResearchPractice MgmtPolicy & AdvocacyCareers

Chronic Lung Disease Update

Family physicians are often the first to diagnose and treat individuals with chronic lung conditions. Chronic obstructive pulmonary disease affects more than 10% of the adult population and is the fourth-leading cause of mortality in the United States. Asthma is the most common chronic condition in childhood, and its prevalence is increasing in adults. Interstitial lung disease and cystic fibrosis are being managed more effectively so individuals with these conditions are living longer. For family physicians, ongoing challenges in caring for individuals with chronic lung disease include following patients from diagnosis through, possibly, end-of-life care and managing the interactions of chronic lung disease with other common comorbidities.

This edition of FP EssentialsTM will outline advances in the management of these four chronic lung conditions. The monograph should be approximately 10,000 words in length, divided into four sections of approximately 2,500 words each, plus a preface, key practice recommendations, a maximum of 15 tables and figures, recommended readings, and references. The monograph should focus on what’s new in each topic and should answer the key questions listed for each section. Each section should begin with an illustrative case, similar to those in the examples provided, with modifications to emphasize key points.The references listed below include information that should be considered in preparation of this edition of FP EssentialsTM. However, these references are only a useful starting point that should be used to identify additional information to review.

Section One: New Developments in the Diagnosis and Management of Chronic Obstructive Pulmonary Disease

(Note: An edition of FP EssentialsTM on chronic obstructive pulmonary disease [COPD] was published in 2008, so the emphasis of this section of the monograph should be on new developments in COPD.)

Example case: Marcus, 52-year-old man, presents to your office reporting progressive shortness of breath and a cough that produces scant nonbloody phlegm during the past 6 months. The symptoms are interfering with his ability to function in his work as a carpenter. He has smoked 1 to 2 packs of cigarettes daily since he was a young man. While performing lung auscultation, you notice diminished breath sounds and scattered wheezes. Describe the most effective approach to the diagnosis and management of Marcus’s condition.

Key questions to consider:
  • What are the latest updates in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) report as it relates to COPD diagnosis and management?
  • Should the forced expiratory volume in 1 second (FEV1)/forced expiratory volume in 6 seconds (FEV6) ratio replace the FEV1/forced vital capacity (FVC) ratio as a method of detecting airway obstruction?
  • Should spirometry have a role in the diagnosis and management of COPD?
  • Which therapies are most effective in patients with stable COPD?
  • Are steroids indicated in patients with stable COPD?
  • Is the approach to women with COPD different than that for men with COPD?
  • When should oxygen use be considered in patients with stable COPD?
  • What are the potential benefits of self-management education and pulmonary rehabilitation for patients with stable COPD?
  • When should antibiotics be used during an acute exacerbation of COPD?
  • Is lung volume reduction surgery effective in patients with emphysema?
Initial references to consider:
  • Global Strategy for Diagnosis, Management, and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD). January 2009. Available at http://www.goldcopd.org/Guidelineitem.asp?l1=2&l2=1&intId=2003. Accessed September 2009.
  • Qaseem A, Snow V, Shekelle P, et al; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2007;147(9):633-638.
  • Lin K, Watkins B, Johnson T, et al. Screening for chronic obstructive pulmonary disease using spirometry: summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;148(7):535-543.
  • Maclay JD, Rabinovich RA, MacNee W. Update in chronic obstructive pulmonary disease 2008. Am J Respir Crit Care Med. 2009;179(7):533-541.
  • Cazzola M. From large clinical trials to management of COPD in the real world. Ther Adv Respir Dis. 2009;3(1):39-46.
  • Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(20):2407-2416. Erratum in: JAMA. 2009;301(10):1024.
  • Miravitlles M, Anzueto A. Insights into interventions in managing COPD patients: Lessons from the TORCH and UPLIFT studies. Int J Chron Obstruct Pulmon Dis. 2009;4(1):185-201.
  • Casaburi R, ZuWallack R. Pulmonary rehabilitation for management of chronic obstructive pulmonary disease. N Engl J Med. 2009;360(13):1329-1335.
  • Cote CG, Chapman KR. Diagnosis and treatment considerations for women with COPD. Int J Clin Pract. 2009;63(3):486-493.
  • Barnes PJ. Emerging pharmacotherapies for COPD. Chest. 2008;134(6):1278-1286 [Review]. Erratum in: Chest. 2009;135(4):1114.
  • Walters JA, Gibson PG, Wood-Baker R, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2009;(1):CD001288.
  • Effing T, Monninkhof EM, van der Valk PD, et al. Self-management education for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007;(4):CD002990.
  • Lacasse Y, Goldstein R, Lasserson TJ, et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;(2):CD003793.
  • Tiong LU, Gibson PG, Hensley MJ, et al. Lung volume reduction surgery for diffuse emphysema. Cochrane Database Syst Rev. 2008;(3):CD001001.
  • Poole P, Chacko EE, Wood-Baker R, et al. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007;(2):CD002733.

Section Two: New Developments in the Diagnosis and Management of Asthma

Example case: The Smith family moved to the area from another state 6 months ago, and are presenting to your office for the first time. The parents are concerned about their 7-year-old daughter and 4-year-old son, who have each experienced increasing shortness of breath with vigorous activity and a dry cough at nighttime. The mother has a history of childhood asthma. The father smokes 1 pack of cigarettes daily but smokes outside the home. The Smiths recently brought a kitten into their home. Describe the diagnosis and management of asthma in these two children. Based on their ages, should there be differences in the approach to each patient?

Key questions to consider:
  • What is the most accurate method of confirming the diagnosis of asthma?
  • What is the role of spirometry in the diagnosis and management of asthma?
  • What is the potential role of biomarkers in the management of asthma?
  • What is the new step-care approach to asthma and why is it effective?
  • Which therapies are most effective for long-term management of asthma? What is new regarding pharmacotherapy for patients with asthma?
  • How does asthma management differ among age groups (ie, younger children, older children, teenagers, and adults)?
  • How should asthma be managed in pregnant women?
  • What are the potential benefits of self-management education for patients with asthma?
  • What is the most effective approach to outpatient management of acute exacerbation of asthma?
  • What preventive measures should be taken for patients with asthma?
Initial references to consider:
  • National Asthma Education and Prevention Program. Expert Panel Report (EPR-3): Guidelines for the diagnosis and management of asthma–Summary Report 2007. J Allergy Clin Immunol. 2007;120 (5 Suppl):S94-S138. Erratum in: J Allergy Clin Immunol. 2008;121(6):1330.
  • Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180(1):59-99.
  • Apter AJ. Advances in adult asthma diagnosis and treatment and health outcomes, education, delivery, and quality in 2008. J Allergy Clin Immunol. 2009;123(1):35-40 [Review].
  • Moore WC. Update in asthma 2008. Am J Respir Crit Care Med. 2009;179(10):869-874.
  • Robinson PD, Van Asperen P. Asthma in childhood. Pediatr Clin North Am. 2009;56(1):191-226, xii.
  • Schatz M, Dombrowski MP. Asthma in pregnancy. N Engl J Med. 2009;360(18):1862-1869 [Review].
  • Kraft M, Israel E, O’Connor GT. Treatment of mild persistent asthma. N Engl J Med. 2007;356(20):2096-2100.
  • Fanta CH. Asthma. N Engl J Med. 2009;360(10):1002-1014 [Review]. Erratum in: N Engl J Med. 2009;360(16):1685.
  • Currie GP, Douglas JG, Heaney LG. Difficult to treat asthma in adults. BMJ. 2009;338:b494.
  • Dykewicz MS. Occupational asthma: current concepts in pathogenesis, diagnosis and management. J Allergy Clin Immunol. 2009;123(3):519-528; quiz 529-530.
  • Peters SP, Anthonisen N, Castro M, et al; American Lung Association Asthma Clinical Research Centers. Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med. 2007:356(20);2027-2039. Erratum in: N Engl J Med. 2007;357(7):728.
  • Bateman E, Nelson H, Bousquet J, et al. Meta-analysis: Effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med. 2008;149(1):33-42.
  • Cates CJ, Crilly JA, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev. 2008;(3)CD000052.

Section Three: New Developments in the Diagnosis and Management of Interstitial Lung Disease

Example case: Alan, a 53-year-old man, presents to your office because of increasing shortness of breath associated with walking up stairs. He recently retired from the US Navy after a 30-year career in shipbuilding. He smoked as a young man but quit more than 20 years ago. The lung examination results reveal diffuse dry crackles. Describe the diagnosis and management of this man’s condition.

Key questions to consider:
  • What is the most effective diagnostic approach to the patient with suspected idiopathic pulmonary fibrosis? What are the roles of high-resolution computed tomography scan and lung biopsy in diagnosis?
  • Which drugs are associated with pulmonary fibrosis?
  • Which therapies are most effective for long-term management of idiopathic pulmonary fibrosis?
  • When should a patient with idiopathic pulmonary fibrosis be considered for lung transplantation?
  • What is the most effective diagnostic approach to the patient with suspected asbestosis?
  • Which method of lung cancer screening, if any, is recommended for patients with asbestosis?
Initial references to consider:
  • Banks, DE, Shi R, McLarty J, et al. American College of Physicians Consensus Statement on the respiratory health effects of asbestos. Results of a Delphi study. Chest. 2009;135(6):1619-1627.
  • Noth I, Martinez FJ. Recent advances in idiopathic pulmonary fibrosis. Chest. 2007;132(2):637-650 [Review].
  • Verma S, Slutsky AS. Idiopathic pulmonary fibrosis–new insights. N Engl J Med. 2007;356(13):1370-1372.
  • Economidou F, Samara KD, Anotniou KM, et al. Induced sputum in interstitial lung diseases: novel insights in the diagnosis, evaluation and research. Respiration. 2009;77(3):351-358.
  • Bouros D. Interferon gamma for idiopathic pulmonary fibrosis. Lancet. 2009;374(9685):180-182 [Review].
  • Kamp DW. Asbestos-induced lung diseases: an update. Transl Res. 2009;153(4):143-152 [Review].
  • Holland A, Hill C. Physical training for interstitial lung disease. Cochrane Database Syst Rev. 2008;(4):CD006322.
  • Taskar V, Coutlas D. Exposures and idiopathic lung disease. Semin Respir Crit Care Med. 2008;29(6):670-679 [Review].

Section Four: New Developments in the Diagnosis and Management of Cystic Fibrosis

Example case: Gina, a 24-year-old woman, has recently moved to the area and presents to your office for continued management of cystic fibrosis. Her prior physician, a pediatrician, retired a year ago and she recently ran out of her maintenance drug. On examination, she is thin but not frail. The lung examination results reveal adequate air movement with mild scattered rhonchi that easily clear with coughing. She asks you to renew the drug prescription and to review the current treatment plan. Describe the most effective management plan for this patient.

Key questions to consider:
  • What information should be given about screening for the risk of cystic fibrosis to a couple planning to have children?
  • What is the most effective diagnostic approach to the newborn with suspected cystic fibrosis?
  • When should cystic fibrosis be suspected in a child, and what testing should be performed to confirm the diagnosis?
  • What advice should be given when a young adult with cystic fibrosis asks about reproduction, life expectancy, health maintenance, and employment?
  • Which therapies are most effective in the long-term management of cystic fibrosis?
  • Are airway clearance therapies effective in the management of cystic fibrosis?
  • At what intervals should sputum cultures and sensitivities be tested in the patient with a stable condition?
  • What microorganisms are most commonly involved in long-term infection and during exacerbations of illness?
  • What is the difference between suppressive antibiotic therapy and antibiotic treatment during exacerbations?
  • What determines the need for hospital admission for the patient with a cystic fibrosis exacerbation?
  • Which antibiotics should be used in long-term management of cystic fibrosis, and which antibiotics should be used during exacerbations? How and for what time period should they be prescribed?
  • Does lung transplantation increase survival rates among patients with cystic fibrosis? What determines candidacy (or lack of candidacy) for transplantation?
Initial references to consider:
  • Farrell PM, Rosenstein BJ, White TB, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr. 2008;153(2):S4-S14.
  • Flume PA, O’Sullivan BP, Robinson KA, et al; Cystic Fibrosis Foundation, Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007;176(10):957-969.
  • Flume PA, Robinson KA, O’Sullivan BP, et al; Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care. 2009;54(4):522-537.
  • Liou TG, Adler FR, Cox DR, et al. Lung transplantation and survival in children with cystic fibrosis. N Engl J Med. 2007;357(21):2143-2152. Erratum in: N Engl J Med. 2008;359(5):e6.
  • Rosenblatt RL. Lung transplantation in cystic fibrosis. Respir Care. 2009;54(6):777-786; discussion 786-787.
  • Starner TD, McCray PB Jr; American College of Physicians, American Physiological Society. Pathogenesis of early lung disease in cystic fibrosis: a window of opportunity to eradicate bacteria. Ann Intern Med. 2005;143(11):816-822 [Review].
  • Van der Schans CP, Prasad A, Main E. Chest physiotherapy compared to no chest physiotherapy for cystic fibrosis. Cochrane Database Syst Rev. 2009;(1):CD001401.
  • Elphick HE, Mallory G. Oxygen therapy for cystic fibrosis. Cochrane Database Syst Rev. 2008;(4):CD003884.
  • Houston BW, Mills N, Solis-Moya A. Inspiratory muscle training for cystic fibrosis. Cochrane Database Syst Rev. 2008;(4):CD006112.
  • Balfour-Lynn, IM, Welch K. Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev. 2008;(4):CD001915.
Shop Catalog